A focal adhesion kinase inhibitor 16-hydroxy-cleroda-3,13-dien-16,15-olide incorporated into enteric-coated nanoparticles for controlled anti-glioma drug delivery

Colloids and Surfaces B: Biointerfaces

Volumn 141, Issue , 2016, Pages 120-131

  Thiyagarajan, Varadharajan ^a   Lin, Shi Xiang ^a   Lee, Chia Hung ^a   Weng, Ching Feng ^a  

^a NATIONAL DONG HWA UNIVERSITY   (Taiwan)

Author keywords

16 Hydroxy cleroda 3,13 dien 16,15 olide; Cytotoxicity; Drug delivery; Mesoporous silica nanoparticles; Reactive oxygen species

Indexed keywords

CELL CULTURE; CELL DEATH; CYTOTOXICITY; DRUG DELIVERY; ELECTRON MICROSCOPY; ENZYME INHIBITION; GRAVIMETRIC ANALYSIS; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; MESOPOROUS MATERIALS; NANOPARTICLES; ORGANIC POLYMERS; SCANNING ELECTRON MICROSCOPY; SILICA; THERMOGRAVIMETRIC ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; TUMORS; X RAY DIFFRACTION;

16-HYDROXY-CLERODA-3,13-DIEN-16,15-OLIDE; ADSORPTION DESORPTION ISOTHERMS; ENHANCED DISSOLUTIONS; MESOPOROUS SILICA NANOPARTICLES; MITOCHONDRIA MEMBRANE POTENTIALS; PHYSICAL CHARACTERIZATION; POWDER X RAY DIFFRACTION; REACTIVE OXYGEN SPECIES;

CONTROLLED DRUG DELIVERY;

16 HYDROXY CLERODA 3,13 DIEN 16,15 OLIDE; CISPLATIN; COPPER; EUDRAGIT; FOCAL ADHESION KINASE INHIBITOR; MESOPOROUS SILICA NANOPARTICLE; POLYMER; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 16-HYDROXYCLERODA-3,13(14)-DIEN-15,16-OLIDE; ANTINEOPLASTIC AGENT; BIOCOMPATIBLE COATED MATERIAL; DELAYED RELEASE FORMULATION; DITERPENE; DRUG CARRIER; FOCAL ADHESION KINASE; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; NANOPARTICLE; POLYMETHACRYLIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; SILICON DIOXIDE;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; C6 CELL LINE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DEGRADATION; DESORPTION; DRUG COATING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; GLIOMA; GLIOMA CELL LINE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; ISOTHERM; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PH; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE MICROSCOPY; PHARMACOKINETICS; PHARMACOLOGY; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COATED MATERIALS, BIOCOMPATIBLE; DELAYED-ACTION PREPARATIONS; DITERPENES; DRUG CARRIERS; DRUG LIBERATION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLIOMA; HYDROGEN-ION CONCENTRATION; MALE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; POLYMETHACRYLIC ACIDS; PROTEIN KINASE INHIBITORS; RATS; SILICON DIOXIDE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY; X-RAY DIFFRACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956706069     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.01.038     Document Type: Article

References (47)

1. Kleihues P., Leslie S.H. World Health Organization classification of tumors. Cancer 2000, 88:2887.
2. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359:492-507.
3. De Angelis L.M. Brain tumors. N. Engl. J. Med. 2001, 344:114-123.
4. van den Bent M.J., Hegi M.E., Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer 2006, 42:582-588.
5. Lala S., Pramanick S., Mukhopadhyay S., Bandyopadhyay S., Basu M.K. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J. Drug Target 2004, 12:165-175.
6. Mukherjee P.K., Wahile A. Integrated approaches towards drug development from Ayurveda and other Indian system of medicines. J. Ethnopharmacol. 2006, 103:25-35.
7. Marthanda Murthy M., Subramanyam M., Hima Bindu M., Annapurna J. Antimicrobial activity of clerodane diterpenoids from Polyalthia longifolia seeds. Fitoterapia 2005, 76:336-339.
8. Chen C.Y., Chang F.R., Shih Y.C., Hsieh T.J., Chia Y.C., Tseng H.Y., Chen H.C., Chen S.J., Hsu M.C., Wu Y.C. Cytotoxic constituents of Polyalthia longifolia var. pendula. J. Nat. Prod. 2000, 63:1475-1478.
9. Chang F.R., Hwang T.L., Yang Y.L., Li C.E., Wu C.C., Issa H.H., Hsieh W.B., Wu Y.C. Anti-inflammatory and cytotoxic diterpenes from formosan Polyalthia longifolia var. pendula. Planta Med. 2006, 72:1344-1347.
10. Lin Y.H., Lee C.C., Chang F.R., Chang W.H., Wu Y.C., Chang J.G. 16-Hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells. Life Sci. 2011, 89:886-895.
11. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
12. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
13. Hall J.B., Dobrovolskaia M.A., Patri A.K., McNeil S.E. Characterization of nanoparticles for therapeutics. Nanomedicine 2007, 2:789-803.
14. Manju S., Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J. Colloid Interface Sci. 2012, 368:144-151.
15. Kresge C.T., Leonowicz M.E., Roth W.J., Vartuli J.C., Beck J.S. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 1992, 359:710-712.
16. Vallet-Regi M., Ramila A., del Real R.P., Pérez-Pariente J. A new property of MCM-41: drug delivery system. Chem. Mater. 2001, 13:308-311.
17. Zhang Y., Zhang J., Jiang T., Wang S. Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties. Int. J. Pharm. 2011, 410:118-124.
18. Van Speybroeck M., Mellaerts R., Mols R., Thi T.D., Martens J.A., Van Humbeeck J., Annaert P., Van den Mooter G., Augustijns P. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur. J. Pharm. Sci. 2010, 41:623-630.
19. Gui R., Wang Y., Sun J. Encapsulating magnetic and fluorescent mesoporous silica into thermosensitive chitosan microspheres for cell imaging and controlled drug release in vitro. Colloids Surf. B 2014, 113:1-9.
20. Thomas M.J., Slipper I., Walunj A., Jain A., Favretto M.E., Kallinteri P., Douroumis D. Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. Int. J. Pharm. 2010, 387:272-277.
21. Lu J., Liong M., Zink J.I., Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007, 3:1341-1346.
22. He H., Xiao H., Kuang H., Xie Z., Chen X., Jing X., Huang Y. Synthesis of mesoporous silica nanoparticle-oxaliplatin conjugates for improved anticancer drug delivery. Colloids Surf. B 2014, 117:75-81.
23. Muhammad F., Zhao J., Wang N., Guo M., Wang A., Chen L., Guo Y., Li Q., Zhu G. Lethal drug combination: arsenic loaded multiple drug mesoporous silica for theranostic applications. Colloids Surf. B 2014, 123:506-514.
24. Frezza M., Hindo S., Chen D., Davenport A., Schmitt S., Tomco D., Dou Q.P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des. 2010, 16:1813-1825.
25. Tardito S., Bussolati O., Maffini M., Tegoni M., Giannetto M., Dall'asta V., Franchi-Gazzola R., Lanfranchi M., Pellinghelli M.A., Mucchino C., Mori G., Marchio L. Thioamido coordination in a thioxo-1,2,4-triazole copper(II) complex enhances nonapoptotic programmed cell death associated with copper accumulation and oxidative stress in human cancer cells. J. Med. Chem. 2007, 50:1916-1924.
26. Singh A.P., Kaushik N.K., Verma A.K., Hundal G., Gupta R. Synthesis structure and biological activity of copper(II) complexes of 4-(2-pyridylmethyl)-1,7-dimethyl-1,4,7-triazonane-2,6-dione and 4-(2-pyridylethyl)-1,7-dimethyl-1,4,7-triazonane-2,6-dione. Eur. J. Med. Chem. 2009, 44:1607-1614.
27. Thiyagarajan V., Tsai M.J., Weng C.F. Antroquinonol targets FAK-signaling pathway suppressed cell migration, invasion, and tumor growth of C6 glioma. PLoS One 2015, 10:e0141285.
28. Li G., Ma R., Huang C., Tang Q., Fu Q., Liu H., Hu B., Xiang J. Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms. Neurosci. Lett. 2008, 442:143-147.
29. Kankala R.K., Kuthati Y., Sie H.W., Shih H.Y., Lue S.I., Kankala S., Jeng C.C., Deng J.P., Weng C.F., Liu C.L., Lee C.H. Multi-laminated metal hydroxide nanocontainers for oral-specific delivery for bioavailability improvement and treatment of inflammatory paw edema in mice. J. Colloid Interface Sci. 2015, 458:217-228.
30. Shao J., Li X., Lu X., Jiang C., Hu Y., Li Q., You Y., Fu Z. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf. B 2009, 72:40-47.
31. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials 2009, 30:5757-5766.
32. Macreadie I.G. Copper transport and Alzheimer's disease. Eur. Biophys. J. 2008, 37:295-300.
33. Koca E., Buyukasik Y., Cetiner D., Yilmaz R., Sayinalp N., Yasavul U., Uner A. Copper deficiency with increased hematogones mimicking refractory anemia with excess blasts. Leuk. Res. 2008, 32:495-499.
34. Twomey P.J., Reynolds T.M., Wierzbicki A.S., Viljoen A. The relationship between serum copper and ceruloplasmin in routine clinical practice. Int. J. Clin. Pract. 2008, 62:485-487.
35. Harris Z.L., Gitlin J.D. Genetic and molecular basis for copper toxicity. Am. J. Clin. Nutr. 1996, 63:836S-841S.
36. Bo S., Durazzo M., Gambino R., Berutti C., Milanesio N., Caropreso A., Gentile L., Cassader M., Cavallo-Perin P., Pagano G. Associations of dietary and serum copper with inflammation, oxidative stress, and metabolic variables in adults. J. Nutr. 2008, 138:305-310.
37. Thress K., Kornbluth S., Smith J.J. Mitochondria at the crossroad of apoptotic cell death. J. Bioenergy Biomembr. 1999, 31:321-326.
38. Sekine S., Ichijo H. Mitochondrial proteolysis: its emerging roles in stress responses. Biochim. Biophys. Acta 2015, 1850:274-280.
39. Thiyagarajan V., Lin S.H., Chia Y.C., Weng C.F. A novel inhibitor 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking. Biochim. Biophys. Acta 2013, 1830:4091-4101.
40. Kirshner J.R., He S., Balasubramanyam V., Kepros J., Yang C.Y., Zhang M., Du Z., Barsoum J., Bertin J. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther. 2008, 7:2319-2327.
41. Nagai M., Vo N.H., Shin Ogawa L., Chimmanamada D., Inoue T., Chu J., Beaudette-Zlatanova B.C., Lu R., Blackman R.K., Barsoum J., Koya K., Wada Y. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic. Biol. Med. 2012, 52:2142-2150.
42. Bhatnagar P., Patnaik S., Srivastava A.K., Mudiam M.K., Shukla Y., Panda A.K., Pant A.B., Kumar P., Gupta K.C. Anti-cancer activity of bromelain nanoparticles by oral administration. J. Biomed. Nanotechnol. 2014, 10:3558-3575.
43. Terwogt J.M., Schellens J.H., Huinink W.W., Beijnen J.H. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat. Rev. 1999, 25:83-101.
44. Zhao L., Feng S.S. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J. Pharm. Sci. 2010, 99:3552-3560.
45. Zhang L., Wang S., Zhang M., Sun J. Nanocarriers for oral drug delivery. J. Drug Target. 2013, 21:515-527.
46. Jiang X., Xin H., Ren Q., Gu J., Zhu L., Du F., Feng C., Xie Y., Sha X., Fang X. Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials 2014, 35:518-529.
47. Xin H., Sha X., Jiang X., Zhang W., Chen L., Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012, 33:8167-8176.